Abecma
BMS third quarter revenues increased 8 percent to $11.90 billion, with its growth portfolio now making up half of total revenues.
BMS, 2seventy End Phase III Trial of Maintenance Abecma in Multiple Myeloma Due to Low Enrollment
The firms said the trial had enrolled only 10 percent of the target study population after one year.
Meta-Analysis Questions FDA Warning on Secondary Cancer Risks With CAR T-Cell Therapies
Researchers analyzed two dozen studies and found similar rates of second primary cancers in patients receiving CAR T-cell and standard therapies.
Sales of the CAR T-cell therapy continue to grow helped by BMS's expansion of its cell manufacturing facilities.
Novo Nordisk Scoops up 2seventy's Hemophilia A Program, Gene Editing Technology
The deal, which is worth up to $40 million, will allow 2seventy to maintain its focus on advancing the multiple myeloma CAR T-cell therapy Abecma.
Apr 25, 2024